薬剤性 QT 延長症候群に関するデータベースの構築

仁ノ内絵里¹、長田和士¹、金子貴俊³、鈴木聡子³
櫻田大也¹、佐藤信範¹¹、岸田 浩²、上田志朗¹¹

1) 千葉大学大学院薬学研究院 医薬品情報学研究室
²⁾ 日本医科大学第一内科
³⁾ データインデックス株式会社

[特別掲載]

Development of a Database for Drug-induced Long QT Syndrome

Eri Ninouchi¹, Kazushi Osada¹, Takatoshi Kaneko³, Satoko Suzuki³ Tomoya Sakurada¹, Nobunori Satoh^{*1}, Hiroshi Kishida², Shiro Ueda¹

2) Department of Internal Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan

3) Data Index Co., Ltd, 1-9-11, Kaigan, Minato-ku, Tokyo, 105-0022, Japan

(Received November 11, 2005) Accepted December 25, 2005)

Abstract

Objective: The long QT syndrome (LQTS) is characterized by prolongation of the QT interval, causing torsades de pointes and sudden cardiac death. LQTS is caused by various drugs, so it is important to determine new and effective means of info-service to prevent it. We assessed the incidence of drug-induced LQTS, searched for the drugs which cause it by drug interaction, and developed a search engine database.

Design and Methods: As a test data, we extracted the drugs which cause LQTS by drug interaction and the reported case reports. Drugs which are known to cause LQTS by drug interaction were looked up in package inserts in Japan. A literature search was done to identify articles that presented data on drug-associated LQTS events. Based on the information, a database was developed.

Results: 27 drugs were found in package insert research, and 129 case reports were found in the literature. The database was designed to allow users to: (1) search for the drugs which cause LQTS due to drug interaction and the mechanism of interaction (e.g., metabolic inhibition, the additive action of administration of two or more medicines causing LQTS, etc.); (2) search for case reports of drug-associated LQTS; and (3) read such reports and the information on package inserts.

Conclusions: We can grasp the pertinent information on drug-induced LQTS systematically and quickly with this database. We anticipate this system will also have a wide range of application for other adverse events.

¹⁾ Department of Drug Information and Communication, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku Chiba City, 260-8675, Japan